NCT06816771

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Evaluation of Efficacy and Safety of Pazopanib Combined with TGI/CIV(nab⁃Paclitaxel+ Gemcitabine + Ifosfamide/cyclophosphamide +Irinotecan + Vinorelbine) in the Treatment for Children or Adolescents with Recurrent/refractory Rhabdomyosarcoma--an Open-label, Single-arm, Single-cente,phase II Clinical Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (estimated)
• Sponsor: Shandong Cancer Hospital and Institute · Academic / Other
• Sex: All
• Age: 2 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.

Conditions

• Rhabdomyosarcoma, Recurrent, Refractory

Interventions

Type	Name	Description
DRUG	pazopanib	Given PO The dosage will be determined according to the participant's body surface area, with body surface area less than 0.75, 1 tablet, and 2 tablets for body surface area greater than 1. 0.75-1,1.5 tablets.
DRUG	TGI chemotherapy	TGI chemotherapy (nab⁃Paclitaxel+ gemcitabine + ifosfamide)
DRUG	CIV chemotherapy	CIV chemotherapy (cyclophosphamide +Irinotecan + vinorelbine)

Timeline

• Start date: 2025-02-01
• Primary completion: 2025-12-31
• Completion: 2026-12-31
• First posted: 2025-02-10
• Last updated: 2025-02-10

Locations

1 site across 1 country: China